Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 9/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | CBFB | Q13951 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24338409 | 0.91 | IRAK4 (0.43) | IRAK4FLT3HSD17B10PDE4DCBFB | |
| SCHEMBL3078992 | 0.87 | IRAK4 (0.41) | IRAK4FLT3HSD17B10PDE4DKDM4E | |
| SCHEMBL3436681 | 0.80 | NOTUM (0.42) | HSD17B10PDE4DKDM4EALDH1A1MAPT | |
| SCHEMBL30177201 | 0.79 | IRAK4 (0.43) | IRAK4FLT3HSD17B10KDM4EALDH1A1 | |
| SCHEMBL3067040 | 0.79 | IRAK4 (0.46) | IRAK4FLT3HSD17B10KDM4EALDH1A1 | |
| SCHEMBL3436679 | 0.77 | MAPT (0.56) | HSD17B10KDM4EALDH1A1MAPTNSD2 | |
| SCHEMBL5764836 | 0.74 | PARP1 (0.44) | MET | |
| SCHEMBL24339225 | 0.74 | HSD17B10 (0.36) | IRAK4HSD17B10METTHRB | |
| SCHEMBL13607537 | 0.73 | IRAK4 (0.39) | IRAK4HSD17B10KDM4EALDH1A1MAPT | |
| SCHEMBL15687221 | 0.72 | MET (0.47) | HSD17B10CBFBMETTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | IRAK4 4325/4885FLT3 4217/4885HSD17B10 1604/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | IRAK4 4325/4885FLT3 4217/4885HSD17B10 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.